CEACAM5 and adenocarcinoma: Among them, three indicators including serum positive CEA (OR, 2.18; 95%CI, 1.86–2.57; p < 0.001), T4 stage (OR, 2.61; 95%CI, 1.78–3.94; p < 0.001), non-adenocarcinoma (OR, 2.01; 95%CI, 1.30–3.14; p = 0.002) had the largest impact on multiple metastases (Figure 3).